In recent years, several studies have suggested that elevated mRNA expression of ADAM9 shortens the overall survival of pancreatic cancer patients [85], a finding that was confirmed by immunohistochemistry [24]. This evidence concerns the gene ADAM9 and familial pancreatic carcinoma.